NO980221L - Fremgangsmåte for behandling av tykktarmsadenomer - Google Patents

Fremgangsmåte for behandling av tykktarmsadenomer

Info

Publication number
NO980221L
NO980221L NO980221A NO980221A NO980221L NO 980221 L NO980221 L NO 980221L NO 980221 A NO980221 A NO 980221A NO 980221 A NO980221 A NO 980221A NO 980221 L NO980221 L NO 980221L
Authority
NO
Norway
Prior art keywords
procedure
treatment
patient
pghs
colon adenomas
Prior art date
Application number
NO980221A
Other languages
English (en)
Norwegian (no)
Other versions
NO980221D0 (no
Inventor
Stacia Kargman
Thomas J Simon
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603470.7A external-priority patent/GB9603470D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of NO980221D0 publication Critical patent/NO980221D0/no
Publication of NO980221L publication Critical patent/NO980221L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lasers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Harvester Elements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Soil Working Implements (AREA)
NO980221A 1995-07-19 1998-01-16 Fremgangsmåte for behandling av tykktarmsadenomer NO980221L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US124095P 1995-07-19 1995-07-19
GBGB9603470.7A GB9603470D0 (en) 1996-02-19 1996-02-19 Method of treating colonic adenomas
PCT/US1996/011761 WO1997003667A1 (en) 1995-07-19 1996-07-15 Method of treating colonic adenomas

Publications (2)

Publication Number Publication Date
NO980221D0 NO980221D0 (no) 1998-01-16
NO980221L true NO980221L (no) 1998-03-18

Family

ID=26308761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980221A NO980221L (no) 1995-07-19 1998-01-16 Fremgangsmåte for behandling av tykktarmsadenomer

Country Status (17)

Country Link
EP (1) EP0839034B1 (es)
KR (1) KR100454624B1 (es)
CN (1) CN1196679A (es)
AT (1) ATE268176T1 (es)
AU (1) AU706089B2 (es)
CA (1) CA2227238C (es)
CZ (1) CZ294516B6 (es)
DE (1) DE69632632T2 (es)
EA (1) EA005073B1 (es)
ES (1) ES2220983T3 (es)
HU (1) HU225506B1 (es)
IL (1) IL122960A (es)
MX (1) MX9800568A (es)
NO (1) NO980221L (es)
NZ (1) NZ312997A (es)
SK (1) SK5298A3 (es)
WO (1) WO1997003667A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
ZA987800B (en) * 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
JP2005522477A (ja) 2002-04-08 2005-07-28 グラクソ グループ リミテッド (2−((2−アルコキシ)−フェニル)−シクロペント−1−エニル)芳香族炭素環式および複素環式酸および誘導体
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
TW200735866A (en) * 2005-11-18 2007-10-01 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
KR20090111847A (ko) * 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Mek 억제제
DK2488145T3 (da) 2009-10-12 2024-07-22 Boehringer Ingelheim Vetmedica Gmbh Beholdere til sammensætninger omfattende meloxicam
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
EP0799218B1 (en) * 1994-12-21 2003-02-19 Merck Frosst Canada & Co. Diaryl-2-(5h)-furanones as cox-2 inhibitors

Also Published As

Publication number Publication date
CN1196679A (zh) 1998-10-21
WO1997003667A1 (en) 1997-02-06
EP0839034A1 (en) 1998-05-06
MX9800568A (es) 1998-04-30
DE69632632D1 (de) 2004-07-08
AU706089B2 (en) 1999-06-10
ATE268176T1 (de) 2004-06-15
IL122960A (en) 2006-07-05
NZ312997A (en) 2000-07-28
EA005073B1 (ru) 2004-10-28
KR100454624B1 (ko) 2004-12-31
DE69632632T2 (de) 2005-05-25
SK5298A3 (en) 1998-12-02
IL122960A0 (en) 1998-08-16
CZ15698A3 (cs) 1998-09-16
CA2227238C (en) 2003-10-28
KR19990029066A (ko) 1999-04-15
CZ294516B6 (cs) 2005-01-12
HUP9901711A3 (en) 2001-02-28
CA2227238A1 (en) 1997-02-06
EP0839034B1 (en) 2004-06-02
NO980221D0 (no) 1998-01-16
EP0839034A4 (en) 2002-06-19
HUP9901711A2 (hu) 1999-09-28
HU225506B1 (en) 2007-01-29
AU6496096A (en) 1997-02-18
EA199800139A1 (ru) 1998-08-27
ES2220983T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
AU1718400A (en) Method for treating pain
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU5624699A (en) Use of 5ht-6 antagonists
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
EE200000685A (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
EP0756869A3 (en) Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO982562L (no) Sammensetning for behandling av smerte
DK0841937T3 (da) Anvendelse af betaglycan til reduktion af ardannelse
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DK0968174T3 (da) Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application